Insider Transactions in Q2 2022 at Inozyme Pharma, Inc. (INZY)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 19
2022
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,355,000
+24.51%
|
$4,065,000
$3.69 P/Share
|
|
Apr 19
2022
|
Sanjay Subramanian SVP, CFO |
BUY
Open market or private purchase
|
Direct |
27,100
+50.0%
|
$81,300
$3.69 P/Share
|
|
Apr 19
2022
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
1,070,000
+28.68%
|
$3,210,000
$3.69 P/Share
|
|
Apr 19
2022
|
Axel Bolte |
BUY
Open market or private purchase
|
Direct |
67,750
+20.76%
|
$203,250
$3.69 P/Share
|
|
Apr 19
2022
|
Henric Bjorn Bjarke SVP, COO |
BUY
Open market or private purchase
|
Direct |
27,100
+25.16%
|
$81,300
$3.69 P/Share
|
|
Apr 19
2022
|
Pivotal Bio Venture Partners Fund I, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,070,000
+28.68%
|
$3,210,000
$3.69 P/Share
|